Timeline: How Co-Diagnostics’ stock price fluctuated as it responded to the coronavirus

Hover over the dots to follow the Salt Lake City company’s journey.

A Co-Diagnostics lab technician manufactures COVID-19 testing kits Friday, March 27, 2020, in Salt Lake City. The company says it has the capacity to produce 50,000 test kits daily from its Salt Lake City facility. (AP Photo/Rick Bowmer)

Editor’s noteThis story is available to Salt Lake Tribune subscribers only. Thank you for supporting local journalism.

As the coronavirus was spreading in early 2020, Salt Lake City-based Co-Diagnostics jumped ahead of the competition.

It gained an early approval for its test for COVID-19 from the European Union.

The next hurdle was getting the federal Food and Drug Administration to approve its request for Emergency Use Authorization to sell its tests in the United States.

Hover over the dots below to see how the company’s stock price went up and down as it received needed approvals, as the accuracy of its tests was questioned, as the SEC made an inquiry and as it was sued by investors who allege its leaders engaged in “manipulative and deceptive practices.”

Read the whole story here.